Analyst: New study confirms that Eli Lilly's tirzepatide is a good product
Eli Lilly has published strong results for its study of the diabetes treatment tirzepatide, which took up the last piece of the puzzle needed for an FDA application, Sydbank analyst Søren Løntoft Hansen says.
BY RITZAU FINANS, TRANSLATED BY CATHERINE BRETT
On Thursday, Eli Lilly released the results of its study of type 2 diabetes treatment tirzepatide, which will compete with Novo Nordisk's Ozempic.
These results were strong, says Sydbank Chief Equity Analyst Søren Løntoft Hansen.
Bavarian has been the center of attention in recent days due to its monkeypox vaccine, and the company has now secured a vaccine contract with another undisclosed country. Consequently, Bavarian has raised its expectations for the full year.